90 related articles for article (PubMed ID: 15050160)
1. The colon displays an absorptive capacity of tacrolimus.
Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
Transplant Proc; 2004 Mar; 36(2):364-6. PubMed ID: 15050160
[TBL] [Abstract][Full Text] [Related]
2. The expression of intestinal CYP3A4 in the piglet model.
Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
Transplant Proc; 2004 Mar; 36(2):361-3. PubMed ID: 15050159
[TBL] [Abstract][Full Text] [Related]
3. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic drug monitoring of immunosuppresants].
Hashida T; Inui K
Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
[TBL] [Abstract][Full Text] [Related]
5. High trough levels of oral FK506 induced by loss of small intestine.
Sano N; Nio M; Shimaoka S; Ishii T; Amae S; Wada M; Ohi R
Pediatr Transplant; 2001 Dec; 5(6):434-8. PubMed ID: 11737769
[TBL] [Abstract][Full Text] [Related]
6. Increased tacrolimus trough levels in association with severe diarrhea, a case report.
Asano T; Nishimoto K; Hayakawa M
Transplant Proc; 2004 Sep; 36(7):2096-7. PubMed ID: 15518758
[TBL] [Abstract][Full Text] [Related]
7. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.
Hebert MF; Fisher RM; Marsh CL; Dressler D; Bekersky I
J Clin Pharmacol; 1999 Jan; 39(1):91-6. PubMed ID: 9987705
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients.
Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction.
Okabe H; Hashimoto Y; Inui KI
J Pharm Pharmacol; 2000 Dec; 52(12):1467-72. PubMed ID: 11197074
[TBL] [Abstract][Full Text] [Related]
10. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus.
Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K
J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737
[TBL] [Abstract][Full Text] [Related]
11. Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor.
Sano N; Nio M; Ishii T; Amae S; Wada M; Nishi K; Endo N; Hayashi Y; Ohi R
Transplant Proc; 2002 May; 34(3):1050-1. PubMed ID: 12034301
[No Abstract] [Full Text] [Related]
12. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats.
Hashimoto Y; Sasa H; Shimomura M; Inui K
Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats.
Ogino Y; Kobayashi E; Fujimura A
J Pharm Pharmacol; 1999 Jul; 51(7):811-5. PubMed ID: 10467956
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients.
Nasiri-Toosi Z; Dashti-Khavidaki S; Nasiri-Toosi M; Khalili H; Jafarian A; Irajian H; Abdollahi A; Sadrai S
Exp Clin Transplant; 2012 Dec; 10(6):586-91. PubMed ID: 22770208
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
[TBL] [Abstract][Full Text] [Related]
17. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
18. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
19. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
[TBL] [Abstract][Full Text] [Related]
20. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
